8IM1 Stock Overview
Engages in the research and distribution of medical implants in Switzerland. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Implantica AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 3.13 |
| 52 Week High | SEK 4.37 |
| 52 Week Low | SEK 1.45 |
| Beta | 1.31 |
| 11 Month Change | -12.93% |
| 3 Month Change | -18.17% |
| 1 Year Change | 109.79% |
| 33 Year Change | -46.22% |
| 5 Year Change | n/a |
| Change since IPO | -62.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8IM1 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -0.5% | 3.8% | 1.3% |
| 1Y | 109.8% | -6.6% | 7.9% |
Return vs Industry: 8IM1 exceeded the German Medical Equipment industry which returned -5.7% over the past year.
Return vs Market: 8IM1 exceeded the German Market which returned 7.2% over the past year.
Price Volatility
| 8IM1 volatility | |
|---|---|
| 8IM1 Average Weekly Movement | 6.6% |
| Medical Equipment Industry Average Movement | 6.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 8IM1 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 8IM1's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 49 | Peter Forsell | www.implantica.com |
Implantica AG engages in the research and distribution of medical implants in Switzerland. The company’s lead product candidate is RefluxStop, a passive CE-marked implant for prevention of gastroesophageal reflux disease. It is also involved in the development of eHealth platform, a digital health system to support its pipeline of smart medical implants designed for a safe and secure control and monitoring over the internet; e-InVivo, a sensor implants to monitor a multitude of health parameters and provide diagnostic information, as well as control treatment from inside the body; wireless energizing platform; and AppetiteControl, an implant to treat obesity by controlling appetite.
Implantica AG Fundamentals Summary
| 8IM1 fundamental statistics | |
|---|---|
| Market cap | €902.62m |
| Earnings (TTM) | -€24.65m |
| Revenue (TTM) | €2.00m |
450.9x
P/S Ratio-36.6x
P/E RatioIs 8IM1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8IM1 income statement (TTM) | |
|---|---|
| Revenue | €2.00m |
| Cost of Revenue | €1.38m |
| Gross Profit | €626.00k |
| Other Expenses | €25.27m |
| Earnings | -€24.65m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 14, 2025
| Earnings per share (EPS) | -0.087 |
| Gross Margin | 31.27% |
| Net Profit Margin | -1,231.07% |
| Debt/Equity Ratio | 0% |
How did 8IM1 perform over the long term?
See historical performance and comparison